vs

Side-by-side financial comparison of Health Catalyst, Inc. (HCAT) and Triumph Financial, Inc. (TFIN). Click either name above to swap in a different company.

Triumph Financial, Inc. is the larger business by last-quarter revenue ($120.1M vs $74.7M, roughly 1.6× Health Catalyst, Inc.). On growth, Triumph Financial, Inc. posted the faster year-over-year revenue change (16.0% vs -6.2%). Over the past eight quarters, Triumph Financial, Inc.'s revenue compounded faster (9.0% CAGR vs -0.0%).

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

The Triumph Motor Company was a British car and motor manufacturing company in the 19th and 20th centuries. The marque had its origins in 1885 when Siegfried Bettmann of Nuremberg formed S. Bettmann & Co. and started importing bicycles from Europe and selling them under his own trade name in London. The trade name became "Triumph" the following year, and in 1887 Bettmann was joined by a partner, Moritz Schulte, also from Germany. In 1889, the businessmen started producing their own bicycles i...

HCAT vs TFIN — Head-to-Head

Bigger by revenue
TFIN
TFIN
1.6× larger
TFIN
$120.1M
$74.7M
HCAT
Growing faster (revenue YoY)
TFIN
TFIN
+22.1% gap
TFIN
16.0%
-6.2%
HCAT
Faster 2-yr revenue CAGR
TFIN
TFIN
Annualised
TFIN
9.0%
-0.0%
HCAT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
HCAT
HCAT
TFIN
TFIN
Revenue
$74.7M
$120.1M
Net Profit
$-91.0M
Gross Margin
Operating Margin
-115.3%
Net Margin
-121.9%
Revenue YoY
-6.2%
16.0%
Net Profit YoY
-340.3%
400.6%
EPS (diluted)
$-1.29

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HCAT
HCAT
TFIN
TFIN
Q4 25
$74.7M
$120.1M
Q3 25
$76.3M
$109.3M
Q2 25
$80.7M
$108.1M
Q1 25
$79.4M
$101.6M
Q4 24
$79.6M
$103.6M
Q3 24
$76.4M
$106.2M
Q2 24
$75.9M
$105.1M
Q1 24
$74.7M
$101.0M
Net Profit
HCAT
HCAT
TFIN
TFIN
Q4 25
$-91.0M
Q3 25
$-22.2M
$1.7M
Q2 25
$-41.0M
$4.4M
Q1 25
$-23.7M
$17.0K
Q4 24
$-20.7M
$3.8M
Q3 24
$-14.7M
$5.3M
Q2 24
$-13.5M
$2.7M
Q1 24
$-20.6M
$4.2M
Gross Margin
HCAT
HCAT
TFIN
TFIN
Q4 25
Q3 25
52.6%
Q2 25
Q1 25
Q4 24
Q3 24
47.5%
Q2 24
Q1 24
Operating Margin
HCAT
HCAT
TFIN
TFIN
Q4 25
-115.3%
Q3 25
-22.9%
1.2%
Q2 25
-46.0%
7.3%
Q1 25
-25.4%
0.1%
Q4 24
-22.0%
5.6%
Q3 24
-17.9%
5.9%
Q2 24
-20.8%
3.4%
Q1 24
-30.5%
4.7%
Net Margin
HCAT
HCAT
TFIN
TFIN
Q4 25
-121.9%
Q3 25
-29.1%
1.6%
Q2 25
-50.8%
4.1%
Q1 25
-29.9%
0.0%
Q4 24
-26.0%
3.7%
Q3 24
-19.3%
5.0%
Q2 24
-17.8%
2.6%
Q1 24
-27.6%
4.1%
EPS (diluted)
HCAT
HCAT
TFIN
TFIN
Q4 25
$-1.29
Q3 25
$-0.32
$0.04
Q2 25
$-0.59
$0.15
Q1 25
$-0.35
$-0.03
Q4 24
$-0.33
$0.13
Q3 24
$-0.24
$0.19
Q2 24
$-0.23
$0.08
Q1 24
$-0.35
$0.14

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HCAT
HCAT
TFIN
TFIN
Cash + ST InvestmentsLiquidity on hand
$95.7M
$248.5M
Total DebtLower is stronger
$153.3M
Stockholders' EquityBook value
$245.8M
$941.8M
Total Assets
$502.6M
$6.4B
Debt / EquityLower = less leverage
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HCAT
HCAT
TFIN
TFIN
Q4 25
$95.7M
$248.5M
Q3 25
$91.5M
$147.2M
Q2 25
$97.3M
$282.3M
Q1 25
$342.0M
$502.9M
Q4 24
$392.0M
$330.1M
Q3 24
$387.3M
$489.3M
Q2 24
$308.3M
$500.7M
Q1 24
$327.8M
$417.0M
Total Debt
HCAT
HCAT
TFIN
TFIN
Q4 25
$153.3M
Q3 25
$153.1M
Q2 25
$153.0M
Q1 25
$382.9M
Q4 24
$382.4M
Q3 24
$345.0M
Q2 24
Q1 24
Stockholders' Equity
HCAT
HCAT
TFIN
TFIN
Q4 25
$245.8M
$941.8M
Q3 25
$331.9M
$919.3M
Q2 25
$347.5M
$912.4M
Q1 25
$376.8M
$893.9M
Q4 24
$365.2M
$890.9M
Q3 24
$355.0M
$885.8M
Q2 24
$357.0M
$874.2M
Q1 24
$357.2M
$872.3M
Total Assets
HCAT
HCAT
TFIN
TFIN
Q4 25
$502.6M
$6.4B
Q3 25
$587.1M
$6.4B
Q2 25
$616.2M
$6.5B
Q1 25
$891.5M
$6.3B
Q4 24
$858.9M
$5.9B
Q3 24
$813.0M
$5.9B
Q2 24
$691.7M
$5.8B
Q1 24
$695.1M
$5.6B
Debt / Equity
HCAT
HCAT
TFIN
TFIN
Q4 25
0.62×
Q3 25
0.46×
Q2 25
0.44×
Q1 25
1.02×
Q4 24
1.05×
Q3 24
0.97×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HCAT
HCAT
TFIN
TFIN
Operating Cash FlowLast quarter
$9.9M
$67.1M
Free Cash FlowOCF − Capex
$9.6M
FCF MarginFCF / Revenue
12.9%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-697.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HCAT
HCAT
TFIN
TFIN
Q4 25
$9.9M
$67.1M
Q3 25
$-464.0K
$24.4M
Q2 25
$-9.0M
$9.8M
Q1 25
$280.0K
$-3.6M
Q4 24
$-3.5M
$58.5M
Q3 24
$6.2M
$26.6M
Q2 24
$1.6M
$21.9M
Q1 24
$10.3M
$-10.7M
Free Cash Flow
HCAT
HCAT
TFIN
TFIN
Q4 25
$9.6M
Q3 25
$-719.0K
$22.4M
Q2 25
$-9.2M
$6.8M
Q1 25
$-390.0K
$-7.9M
Q4 24
$-3.9M
Q3 24
$5.5M
$25.8M
Q2 24
$1.3M
$-31.9M
Q1 24
$10.1M
FCF Margin
HCAT
HCAT
TFIN
TFIN
Q4 25
12.9%
Q3 25
-0.9%
20.5%
Q2 25
-11.4%
6.2%
Q1 25
-0.5%
-7.7%
Q4 24
-4.9%
Q3 24
7.2%
24.3%
Q2 24
1.7%
-30.3%
Q1 24
13.5%
Capex Intensity
HCAT
HCAT
TFIN
TFIN
Q4 25
0.4%
Q3 25
0.3%
1.8%
Q2 25
0.3%
2.8%
Q1 25
0.8%
4.2%
Q4 24
0.5%
Q3 24
0.9%
0.8%
Q2 24
0.4%
51.1%
Q1 24
0.3%
Cash Conversion
HCAT
HCAT
TFIN
TFIN
Q4 25
Q3 25
14.29×
Q2 25
2.22×
Q1 25
-212.82×
Q4 24
15.25×
Q3 24
4.97×
Q2 24
7.95×
Q1 24
-2.58×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

HCAT
HCAT

Recurring Technology$51.9M69%
Professional Services$22.8M31%

TFIN
TFIN

Segment breakdown not available.

Related Comparisons